Prolonged Treatment with Brentuximab Vedotin in Patients with Relapsed/Refractory HL or Systemic ALCL


Prolonged Treatment with Brentuximab Vedotin in Patients with Relapsed/Refractory HL or Systemic ALCL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/11/12)

Forero-Torres A et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Proc ASH 2011;Abstract 3711.

Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.